Results 251 to 260 of about 340,246 (317)

Unraveling 4‐Phenylbutyrate's Therapeutic Role in SLC6A1 Disorders: Pharmacochaperoning Over HDAC Inhibition

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Variants in SLC6A1, encoding the GABA transporter 1 (GAT‐1), cause epilepsy, autism spectrum disorder, and developmental delay via loss of GABA uptake, impaired trafficking, and ER retention. We previously found that 4‐Phenylbutyrate (PBA), an FDA‐approved drug, restores GABA uptake and reduces seizures in SLC6A1‐related disorders ...
Melissa B. DeLeeuw   +5 more
wiley   +1 more source

A Benzimidazole-Based Fluorescent Probe for the Selective Recognition of Cobalt (II) Ions. [PDF]

open access: yesMolecules
Zhu J   +9 more
europepmc   +1 more source

Clinical and Modifiable Factors Associated With Disability and Relapse in MOGAD: A Multicentre Cohort Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Factors associated with relapse course and disability in myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) remain incompletely understood. Objectives To identify clinical and modifiable factors associated with relapse and disability in MOGAD. Methods In this ambispective multicentre cohort study using data from
Yingtao Wang   +23 more
wiley   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Fluorescent lipoprotein probe

Analytical Biochemistry, 1982
Abstract The fluorescent cholesterol analog cholesta-5,7,9(11)triene-3-β-ol was used to label high-density and low-density lipoproteins in vivo (rabbit) and in vitro (human). Rabbit feeding experiments demonstrated that in vivo both the esterified and nonesterified forms of the fluorophore were incorporated by these particles.
R, Bergeron, J, Scott
openaire   +2 more sources

Home - About - Disclaimer - Privacy